Danaher Corporation
DHR-PB
New York Stock Exchange1,261.26
USD
-9.94
- -
CIK
0000313616
ISIN
US2358514097
CUSIP
235851409
Return %
Stock
S&P500
1Y
1.12
26.53
3Y
41.16
76.60
5Y
40.18
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rainer M. Blair
- Full Time Employees
- 79,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- May 11, 2020
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation Danaher Corporation is a global science and technology innovator focused on life sciences, biotechnology, and diagnostics, designing, manufacturing, and marketing professional, medical, research, and industrial products and services. The company operates through three primary segments: Biotechnology, which develops products for therapeutic development including bioprocessing, discovery, and medical applications; Life Sciences, offering tools such as flow cytometry, lab automation solutions, mass spectrometry, microscopy, protein consumables, industrial filtration, and genomic medicines to research disease causes, test therapies, and manufacture drugs, vaccines, and gene editing technologies; and Diagnostics, providing instruments, consumables, software, and services for core lab clinical applications, molecular diagnostics, acute care diagnostics, pathology diagnostics, and flu detection kits through subsidiaries like Cepheid. Danaher Corporation serves end users including core laboratories, hospital laboratories, integrated delivery networks, reference laboratories, specialty laboratories, hospitals, clinics, physicians' offices, scientists, researchers, engineers, and biopharmaceutical producers, with geographic operations spanning over 60 countries including major sales in North America, Western Europe, other developed markets, and high-growth markets. Founded in 1984 by brothers Steven Rales and Mitchell Rales and headquartered at 2200 Pennsylvania Avenue NW in Washington, D.C., the company employs approximately 63,000 associates worldwide and leverages the Danaher Business System for continuous improvement. Recent developments include a January 2025 investment partnership with Innovaccer Inc. through subsidiaries Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled healthcare data analytics, precision diagnostics, and value-based medicine; a May 2025 diagnostic development and commercialization partnership with AstraZeneca plc AstraZeneca plc to scale precision medicine tools and AI-powered tests for patient treatment selection; and the August 2024 acquisition of Genedata AG to bolster life sciences capabilities in accelerating therapeutic discovery and development.